Dear Shareholders and Investors,
2017 was a year of progress in terms of both Pharmaceutical business and Cosmetics business. We restarted the Japanese patient enrollment for pancreatic cancers treated with NC-6004 in Phase III study. Because clinical trials of co-administrations with anyanti-cancer drugs and immune checkpoint inhibitors are emerging worldwide, it ishighly competitive situation on patient enrollments in many cancer treatments. In spite of such situation our biliary tract cancer US/EU study as designated as the Orphan Drug Status by FDA among three indication trials was finalized the enrollment of 50 patients and then entered into the observation period. The US Phase I/II study of NC-6300 against the soft tissue sarcoma is proceeding smoothly because the indication is niche.
In November we successfully licensed VB-111, a groundbreaking gene therapy drug from Israel VBL Therapeutics to develop and market in Japan. We expect to start clinical program in the middle of this year and to file BLA as NDA in 2020. In Cosmetics business we launched “Depth for Share” for women in September, following sales of “Depth” for men’s hair restoration cosmetics. It is very good feedback from customers. And we will move to a fulfilling net sales jointly with Albion this year.
Our theme of this year is "Selection and Focus". We will draw out all synergy effects to the utmost and create further value. We appreciate your continuous support for ouractivities.
Ichiro Nakatomi, PhD
President & CEO
January 1, 2018